CAR-001

N/A

Report date: 2023/12/26 20:04:01

Base Information

Drug NameCAR-001

Drug Alias NameCAR-001CAR001CAR BiTE γδTCD3ε Nb-BiTENb-CAR.BiTE-γδT PD-L1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapy

Mechanisms of ActionHLA class I histocompatibility antigen, alpha chain G modulators

TargetsHLA class I histocompatibility antigen, alpha chain G

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEver Supreme Bio Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesEver Supreme Bio Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A